HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO) (“ReGen” or the “Company”) announced today that it recently completed the second of a two stage private placement of approximately $1.7 million in common stock for combined gross proceeds of approximately $9 million. The proceeds will support the launch of the Company’s Menaflex™ collagen meniscus implant device in the U.S., which recently received FDA clearance.
